Skip to main navigation Skip to search Skip to main content

MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

  • Jens Hillengass
  • , Adam D. Cohen
  • , Michel Delforge
  • , Hermann Einsele
  • , Hartmut Goldschmidt
  • , Katja Weisel
  • , Marc Steffen Raab
  • , Christof Scheid
  • , Jordan M. Schecter
  • , Kevin C. de Braganca
  • , Helen Varsos
  • , Tzu min Yeh
  • , Pankaj Mistry
  • , Tito Roccia
  • , Christina Corsale
  • , Muhammad Akram
  • , Lida Pacaud
  • , Tonia Nesheiwat
  • , Mounzer Agha
  • , Yael C. Cohen
  • Roswell Park Cancer Institute
  • University of Pennsylvania
  • KU Leuven
  • University of Würzburg
  • Heidelberg University 
  • University of Hamburg
  • University of Cologne
  • Johnson & Johnson
  • Legend Biotech
  • University of Pittsburgh

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Neuroscience